Lamotrigine monotherapy

Calabrese, J.R., Bowden, CX., Sachs, G.S., et al A double-blind placebo-controlled study of lamotrigine monotherapy in patients with bipolar I depression. J. Clin. 

Ueberall MA. Normal growth during lamotrigine monotherapy in pediatric epilepsy patients—a prospective evaluation of 103 children and adolescents. Epilepsy Res 2001 46(l) 63-7. 

Biton V, Mirza W, Montouris G, Vuong A, Hammer AE, Barrett PS. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology 2001 56(2) 172-7. 

Gidal BE, Sheth R, Parnell J, et al. Evaluation of VPA dose and concentration effects on lamotrigine pharmacokinetics implications for conversion to lamotrigine monotherapy. Epilepsy Res 2003 57 85-93. 

Brodie MJ, Chadwick DW, Anhut H, Otte A, Messmer SL, Maton S, Sauermann W, Murray G, Garofalo EA Gabapentin Study Group 945-212. Gabapentin versus lamotrigine monotherapy a double-blind comparison in newly diagnosed epilepsy. Epilepsia 2002 43(9) 993-1000. 

In 126 patients with carbamazepine-resistant or valproate-resistant epilepsy given lamotrigine, 50% during add-on therapy and 53% during lamotrigine monotherapy had at least 50% reduction in total seizures (15). There were adverse events in 49 patients, including respiratory tract infections n — 11), dizziness (n — 8), headache (n = 7), diplopia (n = 5), tremor (n = 5), somnolence (n — 4), insomnia (n = 4), nausea (n — 4), and weakness (n = 3). Treatment was discontinued in nine patients because of adverse events, in five cases because of rash. 

Barron TF, Hunt SL, Hoban TF, Price ML. Lamotrigine monotherapy in children. Pediatr Neurol 2000 23(2) 160-3. 

Steiner TJ, Dellaportas Cl, Findley LJ, Gross M, Gibberd FB, Perkin GD, Park DM, Abbott R. Lamotrigine monotherapy in newly diagnosed untreated epilepsy a double-blind comparison with phenytoin. Epilepsia 1999 40(5) 601-7. 

Pisani F, Xiao B, Fazio A, Spina E, Perucca E, Tomson T, Single dose pharmacokinetics of carbamazepine-10,11-epoxide in patients on lamotrigine monotherapy. Epilepsy Res (1994) 19,245-8,... 

Phenytoin is a known hepatic enzyme inducer, which increases lamotrigine metabolism. The recommended starting dose and long-term maintenance dose of lamotrigine in patients already taking phenytoin is twice that of patients receiving lamotrigine monotherapy. 

Zeng K, Wang X, Xi Z, Yan Y. Adverse effects of carbamazepine, phenytoin, valproate and lamotrigine monotherapy in epileptic adult Chinese patients. Clin Neurol Neurosurg 2010 112(4) 291-5. 

In a retrospective study of lamotrigine monotherapy for seizure control in 72 children and adolescents with epilepsy, the mean follow-up period was 33 months [139. In six patients lamotrigine was withdrawn because of adverse events (rash 4, low white cell count 1, severe sleepiness 1). Rashes occurred 2-3 weeks after the start of therapy in four patients. 

Holmes GL, Frank LM, Sheth RD, Philbrook B, Wooten JD, Vuong A, Kerls S, Hammer AE, Messenheimer J. Lamotrigine monotherapy for newly diagnosed typical absence seizures in children. Epilepsy Res 2008 82(2-3) 124-32. 

Valencia I, Pifiol-Ripoll G, Khurana DS, Hardison HH, Kothare SV, Melvin JJ, Marks A, Legido HG. Efficacy and safety of lamotrigine monotherapy in children and adolescents with epilepsy. Eur J Paediatr Neurol 2009 13(2) 141-5. 

Frey LC, Strom LA, Shrestha A, Spitz MC. End-of-dose emergent psychopathology in ambulatory patients with epilepsy on stable-dose lamotrigine monotherapy a case series of six patients. Epilepsy Behav 2009 15(4) 521-3. 

---